Avidity Biosciences Overview
- Year Founded
-
2012
- Status
-
Acquired/Merged
- Employees
-
428
- Latest Deal Type
-
M&A
- Latest Deal Amount
-
$10.8B
Avidity Biosciences General Information
Description
Avidity Biosciences Inc is a biopharmaceutical company committed to delivering a new class of RNA therapeutics called Antibody Oligonucleotide Conjugates, or AOCs. The company's pipeline currently has three programs in potentially registrational clinical trials: DM1, FSHD, and DMD. The segments includes following: Del-zota for DMD44, Del-desiran for DM1, Del-brax for FSHD.
Contact Information
Website
www.aviditybiosciences.com(Operating Subsidiary)
Corporate Office
- 3020 Callan Road
- San Diego, CA 92121
- United States
Corporate Office
- 3020 Callan Road
- San Diego, CA 92121
- United States
Avidity Biosciences Valuation & Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 12. Merger/Acquisition | 27-Feb-2026 | $10.8B | Completed | Generating Revenue | ||
| 11. 2PO | 10-Sep-2025 | Completed | Generating Revenue | |||
| 10. 2PO | 15-Aug-2024 | Completed | Generating Revenue | |||
| 9. 2PO | 12-Jun-2024 | Completed | Generating Revenue | |||
| 8. PIPE | 04-Mar-2024 | Completed | Generating Revenue | |||
| 7. IPO | 12-Jun-2020 | Completed | Generating Revenue | |||
| 6. Later Stage VC (Series C) | 13-Nov-2019 | Completed | Generating Revenue | |||
| 5. Later Stage VC | 22-Apr-2019 | Completed | Generating Revenue | |||
| 4. Corporate | 17-Oct-2018 | $25M | Completed | Generating Revenue | ||
| 3. Later Stage VC (Series B) | 05-Jan-2017 | $16M | $25M | Completed | Startup |
Avidity Biosciences Comparisons
Industry
Financing
Details
Avidity Biosciences Competitors (38)
One of Avidity Biosciences’s 38 competitors is Dyne Therapeutics, a Formerly VC-backed company based in Waltham, MA.
| Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
|---|---|---|---|---|---|---|
| Dyne Therapeutics | Formerly VC-backed | Waltham, MA | ||||
| BioNTech | Formerly VC-backed | Mainz, Germany | ||||
| Arcturus Therapeutics Holdings | Formerly VC-backed | San Diego, CA | ||||
| Protagonist Therapeutics | Formerly VC-backed | Newark, CA | ||||
| Bicycle Therapeutics | Formerly VC-backed | Cambridge, United Kingdom |
Avidity Biosciences Patents
Avidity Biosciences Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| US-20260258160-A1 | Novel preparation of oligonucleotide conjugates using transition metals or salts thereof | Pending | 19-Dec-2024 | ||
| US-20260191980-A1 | Methods of treating cardiomyopathy using prkag2-targeting antibody-oligonucleotide conjugates | Pending | 08-Nov-2024 | ||
| US-20260153519-A1 | Novel biomarker for determining disease activity or prognosis of facioscapulohumeral muscular dystrophy | Pending | 30-Oct-2024 | ||
| WO-2026096668-A2 | Novel biomarker for determining disease activity or prognosis of facioscapulohumeral muscular dystrophy | Pending | 30-Oct-2024 | ||
| WO-2026096668-A3 | Novel biomarker for determining disease activity or prognosis of facioscapulohumeral muscular dystrophy | Pending | 30-Oct-2024 | G01N33/6887 |
Avidity Biosciences Signals
Avidity Biosciences Former Investors (28)
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds |
|---|---|---|---|---|
| Adage Capital Management | Hedge Fund | Minority | ||
| Alethea Capital Management | Venture Capital | Minority | ||
| Alexandria Venture Investments | Venture Capital | Minority | ||
| Avoro Capital | Venture Capital | Minority | ||
| Boxer Capital | Corporate Venture Capital | Minority |
Avidity Biosciences ESG
Risk Overview
Risk Rating
Updated November, 04, 2026
33.97 | High Risk
Risk Scale
A lower score indicates better sustainability
Negl
0-10
Low
10-20
Med
20-30
High
30-40
Severe
40+
Exposure
Exposure refers to the extent to which a company is exposed to different material ESG issues
Management
Management is related to actions taken to manage ESG issues
Peers Analysis
Peer performance insights compare the company’s ESG performance to the performance of selected peers to help inform future ESG decisions and drive internal performance improvements.
Global
Covered Companies
of 13,592
Rank
Percentile
Pharmaceuticals
Industry
of 852
Rank
Percentile
Biotechnology
Subindustry
of 431
Rank
Percentile
Avidity Biosciences FAQs
-
When was Avidity Biosciences founded?
Avidity Biosciences was founded in 2012.
-
Where is Avidity Biosciences headquartered?
Avidity Biosciences is headquartered in San Diego, CA.
-
What is the size of Avidity Biosciences?
Avidity Biosciences has 428 total employees.
-
What industry is Avidity Biosciences in?
Avidity Biosciences’s primary industry is Drug Discovery.
-
Is Avidity Biosciences a private or public company?
Avidity Biosciences is a Private company.
-
What is the current valuation of Avidity Biosciences?
The current valuation of Avidity Biosciences is .
-
What is Avidity Biosciences’s current revenue?
The current revenue for Avidity Biosciences is .
-
How much funding has Avidity Biosciences raised over time?
Avidity Biosciences has raised $2.15B.
-
Who are Avidity Biosciences’s investors?
Adage Capital Management, Alethea Capital Management, Alexandria Venture Investments, Avoro Capital, and Boxer Capital are 5 of 28 investors who have invested in Avidity Biosciences.
-
Who are Avidity Biosciences’s competitors?
Dyne Therapeutics, BioNTech, Arcturus Therapeutics Holdings, Protagonist Therapeutics, and Bicycle Therapeutics are some of the 38 competitors of Avidity Biosciences.
-
When was Avidity Biosciences acquired?
Avidity Biosciences was acquired on 27-Feb-2026.
-
Who acquired Avidity Biosciences?
Avidity Biosciences was acquired by Novartis.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process